Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Suzhou Kintor Starts US Trial of ALK-1 mAb for Hepatocellular Carcinoma

publication date: May 4, 2022

Suzhou Kintor Pharma dosed the first patient in a US Phase II trial of its ALK-1 antibody in combination with Opdivo (nivolumab) to treat advanced Hepatocellular Carcinoma. Kintor believes the ALK-1 antibody is a potential first-in-class, fully human IgG2 neutralizing mAb. It inhibits BMP9, TGFβ through ALK-1 receptor-mediated signal transduction and tumor angiogenesis. In 2018, Kintor acquired global rights to the ALK-1 antibody from Pfizer. The Phase II trial will enroll 105 patients who were intolerant of checkpoint inhibitors or progressed after a first-line round of checkpoint therapy. More details....

Stock Symbol: (HK: 9939)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital